Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -7.26 is 1058% below its 5-year average of -0.63, near the low end of its 5-year range (-7.26–-0.07).
341.34% below its 12-month average of -1.65.
Reported quarterly EPS; no daily interpolation. Q4 FY2026 (2026-06-30): -0.91.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 29 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:27:55.645Z. Historical observations retain their original dates. Historical series through 2025-11-14.
EARNINGS PER SHARE (EPS)
-7.26
EARNINGS PER SHARE (EPS) AVG TTM
-1.65
EARNINGS PER SHARE (EPS) AVG 3Y
-0.89
EARNINGS PER SHARE (EPS) AVG 5Y
-0.63
EARNINGS PER SHARE (EPS) AVG 10Y
-0.42
EARNINGS PER SHARE (EPS) AVG 15Y
-0.17
EARNINGS PER SHARE (EPS) AVG 20Y
-0.19
CURRENT VS TTM AVG
-341.34%
CURRENT VS 3Y AVG
-718.09%
CURRENT VS 5Y AVG
-1057.67%
CURRENT VS 10Y AVG
-1622.14%
CURRENT VS 15Y AVG
-4156.80%
CURRENT VS 20Y AVG
-3787.98%
Neuphoria Therapeutics Inc.
Market Cap
$18.73M
Earnings Per Share (EPS)
-7.26
TTM Avg
-1.65
3Y Avg
-0.89
5Y Avg
-0.63
Market Cap
$18.67M
Earnings Per Share (EPS)
-10.58
TTM Avg
-21.77
3Y Avg
-25.72
5Y Avg
-24.83
Market Cap
$19.20M
Earnings Per Share (EPS)
-0.25
TTM Avg
-0.29
3Y Avg
-0.28
5Y Avg
-0.20
Market Cap
$19.54M
Earnings Per Share (EPS)
-0.89
TTM Avg
-2.16
3Y Avg
-1.83
5Y Avg
-1.83
Market Cap
$19.72M
Earnings Per Share (EPS)
-32.95
TTM Avg
-46.02
3Y Avg
-111.83
5Y Avg
-112.54
Market Cap
$17.53M
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.90
3Y Avg
-9.28
5Y Avg
-9.88
Market Cap
$17.21M
Earnings Per Share (EPS)
-16.36
TTM Avg
46.76
3Y Avg
-158.09
5Y Avg
-209.03
Market Cap
$17.19M
Earnings Per Share (EPS)
-1.87
TTM Avg
-0.88
3Y Avg
-1.76
5Y Avg
-2.28
Market Cap
$17.09M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.99
3Y Avg
-1.87
5Y Avg
-3.18
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.73M | -7.26 | -1.65 | -0.89 | -0.63 |
| NextCure, Inc. (NXTC)vs › | $18.67M | -10.58 | -21.77 | -25.72 | -24.83 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.20M | -0.25 | -0.29 | -0.28 | -0.20 |
| Actuate Therapeutics Inc (ACTU)vs › | $19.54M | -0.89 | -2.16 | -1.83 | -1.83 |
| P3 Health Partners Inc. (PIII)vs › | $19.72M | -32.95 | -46.02 | -111.83 | -112.54 |
| Cosmos Health Inc. (COSM)vs › | $17.53M | -0.66 | -0.90 | -9.28 | -9.88 |
| PAVmed Inc. (PAVM)vs › | $17.21M | -16.36 | 46.76 | -158.09 | -209.03 |
| Lipocine Inc. (LPCN)vs › | $17.19M | -1.87 | -0.88 | -1.76 | -2.28 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.09M | -0.48 | -0.99 | -1.87 | -3.18 |
| Palatin Technologies, Inc. (PTN)vs › | $16.81M | -4.76 | -17.55 | -9.83 | -7.78 |
Trailing EPS (TTM)
$-7.26
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-06-30 | -3.06 |
| 2025-06-30 | -0.23 |
| 2024-06-30 | -0.10 |
| 2023-06-30 | -0.16 |
| 2022-06-30 | -0.14 |
| 2021-06-30 | -0.07 |
| 2020-06-30 | -0.08 |
| 2019-06-30 | -0.11 |
| 2018-06-30 | -0.34 |
| 2017-06-30 | -0.10 |
| 2016-06-30 | -0.25 |
| 2015-06-30 | -0.29 |
| 2014-06-30 | 0.08 |
| 2013-06-30 | -0.26 |
| 2012-06-30 | -0.11 |
| 2011-06-30 | -0.40 |
| 2010-06-30 | -0.24 |
| 2009-06-30 | -0.22 |
| 2008-06-30 | -0.23 |
| 2007-06-30 | -0.26 |
| 2006-06-30 | -0.23 |
| 2005-06-30 | -0.50 |
| 2004-06-30 | -0.43 |
| 2003-06-30 | -0.61 |
| 2002-06-30 | -0.36 |
| 2001-06-30 | -0.36 |
| 2000-06-30 | -0.41 |
| 1999-06-30 | -0.60 |
